Stocktoria
CG Oncology, Inc. CGON
Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2024-01-25
CG Oncology, Inc. financials (annual)
Bars are annual figures from 2023 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $4.0M | $1.1M | $204,000 |
| R&D expense | $116.6M | $82.1M | $45.8M |
| Operating income | -$190.8M | -$114.7M | -$55.4M |
| Income tax | -$270,000 | $1,000 | $1,000 |
| Net income | -$161.0M | -$88.0M | -$48.6M |
| EPS (diluted) | $-2.08 | $-1.41 | $-15.65 |
| Operating cash flow | -$132.3M | -$78.7M | -$45.7M |
| Free cash flow | -$132.5M | -$78.9M | — |
| Cash & equivalents | $32.5M | $257.1M | $8.3M |
| Inventory | $1.6M | $0 | — |
| Total assets | $791.6M | $754.8M | $199.3M |
| Total liabilities | $39.0M | $21.4M | $14.5M |
| Shareholders' equity | $752.6M | $733.4M | -$123.1M |
Growth · year-over-year · Revenue CAGR 345%
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue growth | +254.7% | +458.3% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.